StemCells, Inc. (STEM) Announces FDA Approval to Initiate Clinical Trial of HuCNS-SC(R) Cells in a Myelin Disease
StemCells, Inc. announced this morning that it has received approval from the FDA to begin a clinical trial of the Company's proprietary HuCNS-SC product candidate (purified human neural stem cells) to treat Pelizaeus-Merzbacher Disease (PMD), a fatal brain disorder that primarily affects young children. As of today, there are no approved treatments for this disease. According to the press release, this is the Company's second FDA-approved clinical trial to evaluate HuCNS-SC cells as a potential treatment for neurodegenerative diseases. The first study to be approved was the Company's Phase I clinical trial of HuCNS-SC cells to treat neuronal ceroid lipofuscinoses…